hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The collective effects of two-layer pancreas preservation, pretransplant islet culture, day
-2 pretransplant immunosuppression, and induction immunosuppression with the FcR-nonbinding
anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala)to facilitate diabetes reversal after
single-donor islet transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute